Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion

• Published in: Cancer Immunology, Immunotherapy Vol. 71; no. 2; pp. 365 - 372
• Main Authors: Takeuchi, Eiji, Okano, Yoshio, Machida, Hisanori, Atagi, Katsuhiro, Kondou, Yoshihiro, Kadota, Naoki, Hatakeyama, Nobuo, Naruse, Keishi, Shinohara, Tsutomu
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Cancer Research; Eosinophilia; Eosinophils - pathology; Female; Follow-Up Studies; Humans; Immunology; Leukocytes (eosinophilic); Leukocytes (neutrophilic); Lung cancer; Lymphocytes; Lymphocytes - pathology; Male; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Neutrophils - pathology; Oncology; Original; Original Article; Patients; Pleural effusion; Pleural Effusion - mortality; Pleural Effusion - pathology; Pleural Effusion - therapy; Pleural Effusion, Malignant - mortality; Pleural Effusion, Malignant - pathology; Pleural Effusion, Malignant - therapy; Pleural fluid; Prognosis; Retrospective Studies; Sex ratio; Survival Rate; Tumors; Better prognosis; Malignant pleural effusion; Survival; Lung cancer; Eosinophilic pleural effusion
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-021-02994-5

Objective Tumor-related eosinophilia may have extended survival benefits for some cancer patients. However, there has been no report on the prognosis difference between eosinophilic pleural effusion (EPE) and non-EPE in lung cancer patients. Our study aimed to investigate the prognosis difference between EPE and non-EPE due to lung cancer. Patients and methods We retrospectively reviewed patients diagnosed with lung cancer who presented with malignant pleural effusion (MPE) between May 2007 and September 2020 at the National Hospital Organization Kochi Hospital. EPE is defined as pleural fluid with a nucleated cell count containing 10% or more eosinophils. Results A total of 152 patients were included: 89 were male (59%). The median age was 74.4 years (range 37–101), and all patients were pathologically shown to have MPE. Most patients (140; 92%) had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0/1. Twenty patients had EPE. The median overall survival (OS) of all 152 lung cancer patients with MPE was 298 days. The median OS of the patients with EPE was 766 days, and the median OS of the patients with non-EPE was 252 days. Kaplan–Meier univariate analysis showed that lung cancer patients with EPE had a significantly better prognosis than patients with non-EPE (P < 0.05). Cox proportional regression analysis showed that EPE, ECOG PS, sex, and the neutrophil-to-lymphocyte ratio in the serum (sNLR) may be independent prognostic factors affecting survival in patients with MPE. Conclusion Lung cancer patients with EPE have a better prognosis than those with non-EPE.